Highlights

Australia recognises India's Covaxin for travellers
Australia has already approved Covishield
Australia has opened its borders after nearly 20 months

Latest news

iQOO Buds Review: Monster Battery and Serious Gaming Chops for under ₹2,000

Repo rate today at 5.25%: how long an RBI decision takes to reach your home loan interest rate

CMF Buds Neo Review: 35dB ANC, 52-Hour Battery and Incredible Value

iQOO Z11 Review: A Balanced Mid-Range Powerhouse

Samsung Galaxy Watch 9 Review: Familiar, Faster And Better Where It Matters

Samsung Galaxy Watch Ultra2 Review: A Smarter, Tougher and Longer-Lasting Ultra

Gabit Smart Ring Review: A Better Way To Track Your Health?

Xiaomi Power Bank 5i 20000 67W Review: A Powerful Travel Companion

Bharat Biotech's Covaxin gets Australia's formal nod for travellers

Name: Bharat Biotech's Covaxin gets Australia's formal nod for travellers
Uploaded: 2021-11-01T15:04:37.000+05:30
Duration: T00M46S
Channel: Editorji News Desk
Description: Australia's medicines and medical devices regulator on Monday formally recognised India’s Covid-19 vaccine Covaxin as the country's border was reopened for the first time in nearly 20 months. This recognition i...

This recognition is for travellers aged 12 and over who have been vaccinated with Covaxin.

Updated: Sep 02, 2022 10:53

Editorji News Desk

Join our WhatsApp Channel

Bharat Biotech's Covaxin gets Australia's formal nod for travellers

Australia's medicines and medical devices regulator on Monday formally recognised India’s Covid-19 vaccine Covaxin as the country's border was reopened for the first time in nearly 20 months.

This recognition is for travellers aged 12 and over who have been vaccinated with Covaxin.

Hyderabad-based Bharat Biotech's Covaxin, and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India.

Also watch: Nod to Covaxin delayed further as WHO has more questions for Bharat Biotech

Australia has already recognised Covishield.

Australia's approval for Covaxin comes at a time when an expert panel of WHO is considering the vaccine-maker's application for emergency use authorisation.